Targeted multidrug delivery system to overcome chemoresistance in breast cancer

Yuan Tang,1 Fariborz Soroush,1 Zhaohui Tong,2 Mohammad F Kiani,1 Bin Wang1,3 1Department of Mechanical Engineering, Temple University, Philadelphia, PA, 2Department of Agricultural and Biological Engineering, University of Florida, Gainesville, FL, 3Department of Biomedical Engineering, Widener Uni...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tang Y, Soroush F, Tong Z, Kiani MF, Wang B
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://doaj.org/article/0356124204ff4931a6d43e054cb4b7dd
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:0356124204ff4931a6d43e054cb4b7dd
record_format dspace
spelling oai:doaj.org-article:0356124204ff4931a6d43e054cb4b7dd2021-12-02T04:33:03ZTargeted multidrug delivery system to overcome chemoresistance in breast cancer1178-2013https://doaj.org/article/0356124204ff4931a6d43e054cb4b7dd2017-01-01T00:00:00Zhttps://www.dovepress.com/targeted-multidrug-delivery-system-to-overcome-chemoresistance-in-brea-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Yuan Tang,1 Fariborz Soroush,1 Zhaohui Tong,2 Mohammad F Kiani,1 Bin Wang1,3 1Department of Mechanical Engineering, Temple University, Philadelphia, PA, 2Department of Agricultural and Biological Engineering, University of Florida, Gainesville, FL, 3Department of Biomedical Engineering, Widener University, Chester, PA, USA Abstract: Chemotherapy has been widely used in breast cancer patients to reduce tumor size. However, most anticancer agents cannot differentiate between cancerous and normal cells, resulting in severe systemic toxicity. In addition, acquired drug resistance during the chemotherapy treatment further decreases treatment efficacy. With the proper treatment strategy, nanodrug carriers, such as liposomes/immunoliposomes, may be able to reduce undesired side effects of chemotherapy, to overcome the acquired multidrug resistance, and to further improve the treatment efficacy. In this study, a novel combinational targeted drug delivery system was developed by encapsulating antiangiogenesis drug bevacizumab into liposomes and encapsulating chemotherapy drug doxorubicin (DOX) into immunoliposomes where the human epidermal growth factor receptor 2 (HER2) antibody was used as a targeting ligand. This novel combinational system was tested in vitro using a HER2 positive and multidrug resistant breast cancer cell line (BT-474/MDR), and in vivo using a xenograft mouse tumor model. In vitro cell culture experiments show that immunoliposome delivery led to a high cell nucleus accumulation of DOX, whereas free DOX was observed mostly near the cell membrane and in cytoplasm due to the action of P-gp. Combining liposomal bevacizumab with immunoliposomal DOX achieved the best tumor growth inhibition and the lowest toxicity. Tumor size decreased steadily within a 60-day observation period indicating a potential synergistic effect between DOX and bevacizumab through the targeted delivery. Our findings clearly indicate that tumor growth was significantly delayed in the combinational liposomal drug delivery group. This novel combinational therapy has great potential for the treatment of patients with HER2/MDR double positive breast cancer. Keywords: immunoliposome, targeted drug delivery, xenograft mouse tumor model, combination therapy, multidrug resistanceTang YSoroush FTong ZKiani MFWang BDove Medical PressarticleImmunoliposometargeted drug deliveryxenograft mouse tumor modelcombination therapymulti-drug resistance.Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 671-681 (2017)
institution DOAJ
collection DOAJ
language EN
topic Immunoliposome
targeted drug delivery
xenograft mouse tumor model
combination therapy
multi-drug resistance.
Medicine (General)
R5-920
spellingShingle Immunoliposome
targeted drug delivery
xenograft mouse tumor model
combination therapy
multi-drug resistance.
Medicine (General)
R5-920
Tang Y
Soroush F
Tong Z
Kiani MF
Wang B
Targeted multidrug delivery system to overcome chemoresistance in breast cancer
description Yuan Tang,1 Fariborz Soroush,1 Zhaohui Tong,2 Mohammad F Kiani,1 Bin Wang1,3 1Department of Mechanical Engineering, Temple University, Philadelphia, PA, 2Department of Agricultural and Biological Engineering, University of Florida, Gainesville, FL, 3Department of Biomedical Engineering, Widener University, Chester, PA, USA Abstract: Chemotherapy has been widely used in breast cancer patients to reduce tumor size. However, most anticancer agents cannot differentiate between cancerous and normal cells, resulting in severe systemic toxicity. In addition, acquired drug resistance during the chemotherapy treatment further decreases treatment efficacy. With the proper treatment strategy, nanodrug carriers, such as liposomes/immunoliposomes, may be able to reduce undesired side effects of chemotherapy, to overcome the acquired multidrug resistance, and to further improve the treatment efficacy. In this study, a novel combinational targeted drug delivery system was developed by encapsulating antiangiogenesis drug bevacizumab into liposomes and encapsulating chemotherapy drug doxorubicin (DOX) into immunoliposomes where the human epidermal growth factor receptor 2 (HER2) antibody was used as a targeting ligand. This novel combinational system was tested in vitro using a HER2 positive and multidrug resistant breast cancer cell line (BT-474/MDR), and in vivo using a xenograft mouse tumor model. In vitro cell culture experiments show that immunoliposome delivery led to a high cell nucleus accumulation of DOX, whereas free DOX was observed mostly near the cell membrane and in cytoplasm due to the action of P-gp. Combining liposomal bevacizumab with immunoliposomal DOX achieved the best tumor growth inhibition and the lowest toxicity. Tumor size decreased steadily within a 60-day observation period indicating a potential synergistic effect between DOX and bevacizumab through the targeted delivery. Our findings clearly indicate that tumor growth was significantly delayed in the combinational liposomal drug delivery group. This novel combinational therapy has great potential for the treatment of patients with HER2/MDR double positive breast cancer. Keywords: immunoliposome, targeted drug delivery, xenograft mouse tumor model, combination therapy, multidrug resistance
format article
author Tang Y
Soroush F
Tong Z
Kiani MF
Wang B
author_facet Tang Y
Soroush F
Tong Z
Kiani MF
Wang B
author_sort Tang Y
title Targeted multidrug delivery system to overcome chemoresistance in breast cancer
title_short Targeted multidrug delivery system to overcome chemoresistance in breast cancer
title_full Targeted multidrug delivery system to overcome chemoresistance in breast cancer
title_fullStr Targeted multidrug delivery system to overcome chemoresistance in breast cancer
title_full_unstemmed Targeted multidrug delivery system to overcome chemoresistance in breast cancer
title_sort targeted multidrug delivery system to overcome chemoresistance in breast cancer
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/0356124204ff4931a6d43e054cb4b7dd
work_keys_str_mv AT tangy targetedmultidrugdeliverysystemtoovercomechemoresistanceinbreastcancer
AT soroushf targetedmultidrugdeliverysystemtoovercomechemoresistanceinbreastcancer
AT tongz targetedmultidrugdeliverysystemtoovercomechemoresistanceinbreastcancer
AT kianimf targetedmultidrugdeliverysystemtoovercomechemoresistanceinbreastcancer
AT wangb targetedmultidrugdeliverysystemtoovercomechemoresistanceinbreastcancer
_version_ 1718401167299444736